Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis.
Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis.
复制标题
血清 IL-10 预测癌症患者更糟糕的结果：荟萃分析。
DOI：
10.1371/journal.pone.0139598
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Huang J
中科院分区：
文献类型：
--
作者：
Zhao S;Wu D;Wu P;Wang Z;Huang J
IL-10是一种重要的免疫抑制细胞因子，在肿瘤微环境中经常升高。有研究报道，血清IL-10过表达与恶性肿瘤患者预后较差相关。在这里，我们进行了一项荟萃分析，以评估癌症患者血清IL-10表达对预后的影响。我们检索了PubMed和EBSCO，以评估IL-10在血清中的表达与癌症患者临床预后的关系。总生存期（OS）为主要预后指标，无病生存期（DFS）为次要预后指标。提取的数据计算成1年、3年和5年生存率的比值比（ORs）和95%置信区间（CI）或P值。使用Mantel-Haenszel固定效应模型对合并数据进行加权。所有统计检验均为双侧检验。这项荟萃分析纳入了来自21项已发表研究的1788名癌症患者。高水平的血清IL-10与恶性肿瘤1年（OR = 3.70, 95% CI = 2.81 ~ 4.87, P < 0.00001）、3年（OR = 3.33, 95% CI = 2.53 ~ 4.39, P < 0.0001）和5年（OR = 2.80, 95% CI = 1.90 ~ 4.10, P < 0.0001）的恶性肿瘤OS恶化显著相关。亚组分析显示，血清IL-10表达与实体瘤和血液恶性肿瘤患者预后的相关性是一致的。IL-10与1年（OR = 3.34, 95% CI = 1.40 ~ 7.94, P = 0.006）和2年（OR = 3.91, 95% CI = 1.79 ~ 8.53, P = 0.0006）较差的DFS也有关联。在大多数类型的癌症中，高表达的IL-10会导致不良的生存。IL-10是一种有价值的生物标志物，可用于实体瘤和血液系统恶性肿瘤的预后预测和靶向IL-10治疗方案。
IL–10 is an important immunosuppressive cytokine which is frequently elevated in tumor microenvironment. Some studies have reported that overexpression of serous IL–10 is correlated with worse outcome in patients with malignant tumor. Here, we conducted a meta-analysis to assess the prognostic impact of serous IL–10 expression in cancer patients. We searched PubMed and EBSCO for studies in evaluating the association of IL–10 expression—in serum and clinical outcome in cancer patients. Overall survival (OS) was the primary prognostic indicator and disease-free survival (DFS) was the secondary indicator. Extracted data were computed into odds ratios (ORs) and 95% confidence interval (CI) or a P value for survival at 1, 3 and 5 years. Pooled data were weighted using the Mantel–Haenszel Fixed-effect model. All statistical tests were two-sided. A total of 1788 patients with cancer from 21 published studies were incorporated into this meta-analysis. High level of serum IL–10 was significantly associated with worse OS at 1-year (OR = 3.70, 95% CI = 2.81 to 4.87, P < 0.00001), 3-year (OR = 3.33, 95% CI = 2.53 to 4.39, P < 0.0001) and 5-year (OR = 2.80, 95% CI = 1.90 to 4.10, P < 0.0001) of cancer. Subgroup analysis showed that the correlation between serous IL–10 expression and outcome of patients with solid tumors and hematological malignancies are consistent. The association of IL–10 with worse DFS at 1-year (OR = 3.34, 95% CI = 1.40 to 7.94, P = 0.006) and 2-year (OR = 3.91, 95% CI = 1.79 to 8.53, P = 0.0006) was also identified. High expression of serous IL–10 leads to an adverse survival in most types of cancer. IL–10 is a valuable biomarker for prognostic prediction and targeting IL–10 treatment options for both solid tumors and hematological malignancies.